Avidity Biosciences (RNA) to Release Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Avidity Biosciences to post earnings of ($1.24) per share and revenue of $1.9820 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, February 23, 2026 at 7:00 AM ET.

Avidity Biosciences Stock Up 0.1%

Shares of NASDAQ:RNA opened at $72.92 on Tuesday. The firm has a fifty day simple moving average of $72.51 and a two-hundred day simple moving average of $61.57. Avidity Biosciences has a 52 week low of $21.51 and a 52 week high of $73.06. The stock has a market capitalization of $11.28 billion, a P/E ratio of -17.44 and a beta of 0.93.

Insiders Place Their Bets

In other news, CFO Michael F. Maclean sold 4,542 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $72.45, for a total transaction of $329,067.90. Following the transaction, the chief financial officer owned 59,290 shares of the company’s stock, valued at approximately $4,295,560.50. This represents a 7.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur A. Levin sold 1,758 shares of the business’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $72.45, for a total value of $127,367.10. Following the completion of the transaction, the director directly owned 16,562 shares of the company’s stock, valued at approximately $1,199,916.90. The trade was a 9.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 58,407 shares of company stock worth $4,226,448. 3.83% of the stock is owned by company insiders.

Institutional Trading of Avidity Biosciences

A number of institutional investors have recently modified their holdings of the company. Wellington Management Group LLP grew its position in shares of Avidity Biosciences by 8.8% in the 3rd quarter. Wellington Management Group LLP now owns 10,065,187 shares of the biotechnology company’s stock worth $438,540,000 after buying an additional 815,497 shares during the last quarter. RA Capital Management L.P. grew its holdings in Avidity Biosciences by 18.9% in the third quarter. RA Capital Management L.P. now owns 8,641,031 shares of the biotechnology company’s stock worth $376,490,000 after purchasing an additional 1,375,000 shares during the last quarter. Pentwater Capital Management LP grew its holdings in Avidity Biosciences by 30,032.5% in the fourth quarter. Pentwater Capital Management LP now owns 6,026,500 shares of the biotechnology company’s stock worth $434,691,000 after purchasing an additional 6,006,500 shares during the last quarter. HBK Investments L P acquired a new position in shares of Avidity Biosciences during the fourth quarter worth $314,847,000. Finally, Polar Capital Holdings Plc lifted its holdings in shares of Avidity Biosciences by 58.0% during the 3rd quarter. Polar Capital Holdings Plc now owns 2,796,760 shares of the biotechnology company’s stock valued at $121,855,000 after purchasing an additional 1,026,373 shares during the last quarter.

Wall Street Analyst Weigh In

RNA has been the subject of several analyst reports. Needham & Company LLC lowered Avidity Biosciences from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research note on Monday, October 27th. Evercore set a $72.00 price target on shares of Avidity Biosciences in a research note on Thursday, December 18th. Wolfe Research lowered shares of Avidity Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. Loop Capital set a $72.00 target price on Avidity Biosciences in a research note on Tuesday, October 28th. Finally, Sanford C. Bernstein downgraded Avidity Biosciences from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $52.00 to $72.00 in a report on Monday, October 27th. Eight analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $69.57.

Avidity Biosciences Company Profile

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.